Adalvo has received DCP approval for Dapagliflozin film-coated tablets ahead of the standard 210-day timeline, allowing strategic preparation for a Day-1 launch. Backed by a strong IP strategy, Adalvo is positioned for fast and competitive market entry.
Developed based on the reference brand Forxiga, Dapagliflozin is indicated for treating insufficiently controlled type 2 diabetes, symptomatic chronic heart failure and chronic kidney disease.
Forxiga had global sales of $11.5 billion in 2023, with a 3-year CAGR of over 30%, according to IQVIA.
Adalvo has one of the broadest diabetes pipelines in the industry, having a diverse range of therapeutic options, including small molecules and peptide-based treatments across both oral and parenteral formulations
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!